Sai Parenterals · forward-looking guidance across the available source record.
Guidance tracker
Management targets Rs 750 crore revenue for FY27 driven by execution of existing long-term contracts, new dossier commercialization, increasing Numed contribution, and momentum in CDMO export business. H2 expected to be heavier than H1.
EBITDA margin guidance of 17% for FY27, up from ~12.3% in FY26, driven by vertical integration benefits as Numed manufacturing shifts to Sai's own facilities.
None of the ongoing Rs 440 crore capex projects will contribute to FY27 financials as most facilities will be commissioned towards end of the year. Full impact expected in FY28.
By FY28, majority of capex program expected operational including Adelaide facility, expanded Indian capacities, EU GMP infrastructure, and R&D center—all contributing to revenue and margin expansion.